Accelerating and
optimizing gene editing
therapeutic development

Cassidy Bio is an AI-driven company providing bespoke solutions that accelerate therapeutic research and development in gene editing, enabling partners to make faster, smarter, and more confident decisions.

Learn More

gRNA design

We empower research teams with tailored predictive platform and data that optimize guide RNA design, predict on/off-target effects, and streamline decision-making across the therapeutic development lifecycle.

Unmet need

The Role of Guide RNAs

Guide RNAs (gRNAs) serve as the 'GPS' for CRISPR systems, directing the editing machinery to precise genetic targets. The design of gRNAs plays a critical role in determining both the efficacy and safety of gene-editing therapeutics.

Clinical Challenges

In clinical settings, suboptimal gRNA design has been associated with adverse outcomes, including the positive selection of unintended insertions or deletions (Indels) and unexpected genotoxic effects in genomic variants.

Industry Direction

As the field advances toward editing multiple gene targets across diverse cell types and platforms, there is an increasing demand to optimize and de-risk gRNA design to ensure safe, effective, and scalable therapeutic applications.

Our Approach

We apply cutting-edge AI-driven predictive tools alongside advanced wet lab capabilities to accelerate, optimize, and de-risk the development of next-generation gene-editing therapies.

Our team is building the first comprehensive predictive platform based on large language models (LLM) for gRNA design — powered by proprietary, clinically relevant genomic data generation, state-of-the-art predictive algorithms, and rigorous wet lab validation.

Accelerate

Rapid gRNA ranking, including on/off-target predictions, delivered within weeks
Expand & Optimize

Comprehensive on/off-target predictions across all potential guides, multiple editing technologies, and diverse cell types
De-Risk

Identification of both high- and low-frequency off-targets with a full genotoxicity profile spanning tens of thousands of genomic variants

Leadership

Rom Kshuk

CEO

Mr. Kshuk is a seasoned biotech entrepreneur. Prior to launching Cassidy Bio, he served as CEO of Future Meat Technologies (now Believer Meats), a global leader in cultured meat. Under his leadership, the company grew from inception to raising $400M from top-tier investors including S2G Ventures, Emerald Technology Ventures, Tyson Foods, and Archer Daniels Midland. Rom previously held roles as Director of Business Development at Evogene, R&D Manager at Oplon Pure Science, and co-founder of a coffee alternative startup. He holds a BSc in Chemistry, Biology, and Computer Science.

Prof. Ayal Hendel

CSO

Prof. Hendel is a leading expert in genome editing and gene therapy, based at Bar-Ilan University in Ramat Gan, Israel. He earned his PhD from the Weizmann Institute of Science and completed postdoctoral training at Stanford University, where he contributed to groundbreaking advances in CRISPR genome editing. His research focuses on developing innovative CRISPR-based therapeutic strategies, particularly for inherited blood and immune system disorders such as severe combined immunodeficiency (SCID).

Dr. Yaniv Shmueli

CTO

Dr. Shmueli brings over 25 years of experience in the technology sector, with a focus on AI and machine learning. Before co-founding Cassidy Bio, he served as Engineering Manager at Meta Platforms, leading applied ML teams in areas such as data discovery, recommendation systems, and information enrichment. At Meta AI, he also contributed as a Senior AI Researcher and co-authored ESM, a large language model for de novo protein design. Yaniv previously served as VP of R&D at Kenshoo (now Skai) and Software Group Manager at Texas Instruments. He holds a PhD in Computer Science from Tel Aviv University.